Kazia Therapeutics Valeur / Action
Quel est le Valeur / Action de Kazia Therapeutics?
Le Valeur / Action de Kazia Therapeutics Limited est 0.07
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics
Que fait Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Entreprises avec valeur / action similaire à Kazia Therapeutics
- Signal Gold a Valeur / Action de 0.07
- Absolute Software a Valeur / Action de 0.07
- Luxxu a Valeur / Action de 0.07
- Manfield Chemical a Valeur / Action de 0.07
- V1 a Valeur / Action de 0.07
- SRG Graphite a Valeur / Action de 0.07
- Kazia Therapeutics a Valeur / Action de 0.07
- Saferoads a Valeur / Action de 0.07
- K9 Gold a Valeur / Action de 0.07
- TWC Tech II a Valeur / Action de 0.07
- Mineworx Technologies a Valeur / Action de 0.07
- China Greenland Broad Greenstate a Valeur / Action de 0.07
- Patriot One Technologies a Valeur / Action de 0.07